The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

For years, the standard advice has been to reduce your daily caloric intake. But a new clinical trial suggests intermittent ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...

Paige Vickers shed 14 stone after growing up struggling with her weight and being bullied by cruel classmates who branded her ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...

Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment ...

Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

U.S. Treasury Secretary Scott Bessent said Thursday he is assembling a list of potential candidates to lead the Federal Reserve, with an announcement expected before the end of 2025.

A rally in big tech drove stocks higher, but the market came well off session highs as traders geared up for Friday’s key jobs report. Bond yields fell. The dollar wavered.